| P50 | author | Keith Flaherty | Q6384357 |
| | Andrzej Niemierko | Q125315729 |
| P2093 | author name string | Kevin S Oh | |
| | Ryan J Sullivan | |
| | Donald P Lawrence | |
| | Helen A Shih | |
| | Daniel A Wattson | |
| | Ryan M Merritt | |
| P2860 | cites work | Improved survival with vemurafenib in melanoma with BRAF V600E mutation | Q24631953 |
| | Safety, activity, and immune correlates of anti-PD-1 antibody in cancer | Q24633070 |
| | NRAS mutation status is an independent prognostic factor in metastatic melanoma | Q27851695 |
| | Improved overall survival in melanoma with combined dabrafenib and trametinib | Q27853091 |
| | Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma | Q27860650 |
| | Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer | Q27860857 |
| | Improved Survival with Ipilimumab in Patients with Metastatic Melanoma | Q27861062 |
| | Ipilimumab plus dacarbazine for previously untreated metastatic melanoma | Q28131634 |
| | Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study | Q28250432 |
| | Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial | Q29614756 |
| | Improved survival with MEK inhibition in BRAF-mutated melanoma | Q29620663 |
| | Temozolomide for the treatment of brain metastases associated with metastatic melanoma: a phase II study | Q33361043 |
| | Determinants of survival in patients with brain metastases from cutaneous melanoma | Q33794890 |
| | Increased permeability of the blood-brain barrier to chemotherapy in metastatic brain tumors: establishing a treatment paradigm | Q34632917 |
| | Melanoma cells show a heterogeneous range of sensitivity to ionizing radiation and are radiosensitized by inhibition of B-RAF with PLX-4032. | Q34634256 |
| | Vemurafenib in patients with BRAF(V600) mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study | Q34658082 |
| | Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma | Q34664981 |
| | Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases | Q35721137 |
| | Impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) on the brain distribution of a novel BRAF inhibitor: vemurafenib (PLX4032) | Q36057973 |
| | Mechanisms limiting distribution of the threonine-protein kinase B-RaF(V600E) inhibitor dabrafenib to the brain: implications for the treatment of melanoma brain metastases | Q36642420 |
| | Targeting hyperactivation of the AKT survival pathway to overcome therapy resistance of melanoma brain metastases | Q37231972 |
| | Pathologic and gene expression features of metastatic melanomas to the brain | Q37512029 |
| | Radiosurgery for melanoma brain metastases in the ipilimumab era and the possibility of longer survival | Q38019011 |
| | Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials | Q38502534 |
| | Oncogenic BRAF induces melanoma cell invasion by downregulating the cGMP-specific phosphodiesterase PDE5A. | Q39610715 |
| | Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma. | Q41675125 |
| | Integrated Molecular and Clinical Analysis of AKT Activation in Metastatic Melanoma | Q42723115 |
| | Number of metastases, serum lactate dehydrogenase level, and type of treatment are prognostic factors in patients with brain metastases of malignant melanoma | Q43995413 |
| | Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial | Q44442912 |
| | Vemurafenib and radiation therapy in melanoma brain metastases | Q44534087 |
| | Patterns of response and progression in patients with BRAF-mutant melanoma metastatic to the brain who were treated with dabrafenib | Q45896654 |
| | BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma | Q48499411 |
| | Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial | Q48594003 |
| | Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. | Q54610975 |
| | Distinguishing Clinicopathologic Features of Patients with V600E and V600K BRAF-Mutant Metastatic Melanoma | Q58024726 |
| | Prognostic factors for survival in melanoma patients with brain metastases | Q85226494 |
| P433 | issue | 1 | |
| P921 | main subject | brain metastasis | Q1620196 |
| P304 | page(s) | 75-84 | |
| P577 | publication date | 2015-04-12 | |
| P1433 | published in | Journal of Neuro-Oncology | Q15752119 |
| P1476 | title | Survival patterns following brain metastases for patients with melanoma in the MAP-kinase inhibitor era. | |
| P478 | volume | 123 | |